Get in Touch

We supported a mid-size company to assess the opportunity for a gene therapy platform they were planning on in-licensing​

  • Access Strategy, Price Optimisation
P4A not only told us what the opportunity is today, but also what we should do between now and launch in 2025 to improve revenues​
Franchise Lead for Regenerative Medicine unit​

Client Challenge

Understand the pricing, access ​and uptake potential of a potential gene therapy platform that the client wished to in-license ​

The pharma company had identified a autologous gene therapy platform ​ being developed in multiple orphan ​ indications as a target for in-licensing

​Although all indications were rare, each had different landscapes and with different patient pathways. While the pivotal clinical trials were completed for 1 indication, they were still ongoing for the other planned indications

P4A Solution

P4A used a combination of secondary research, primary research validation and supported the revenue forecasting exercise to inform the go-/no-go decision​

P4A’s approach required inputs from various internal and external stakeholders:​
  • Secondary research to develop disease landscapes​
  • Primary research with payers and KOLs to ​understand the pricing, access and uptake potential​
  • P4A developed an opportunity optimisation plan and worked with the client to inform the forecast model​
  • Workshop to align on go-/no-go decision ​

The Successful Outcome​

  • Understood the P&R, patient access and competitive landscape for the product in each indication​
  • Provided list & net pricing potential, levels of access restrictions, peak patient share and the shape of the uptake curve that fed in to the forecasting model​
  • Identified impact of label expansion and highlighted the need for changes in the launch sequence to optimise revenue​
  • Identified evidence and market shaping mitigation measures to further optimise the P&R / commercial potential of the product​

Need more details?

Do you want to learn more about the successful outcome for this case study? Are you interested in P4A Services or just want to say Hi?

get in touch

Explore other case studies

Understand evidence requirements beyond clinical trial data for launching an orphan drug in Türkiye & the GCC

  • Access Strategy

Optimising the PRMA potential of an orphan oncology asset in EU4 + UK and Japan

  • Access Strategy, Price Optimisation
p4a-logo-small-retina-white

We are award winning global experts in access for orphan drugs and Cell and Gene Therapies.

Twitter Instagram Youtube Linkedin

About

Services

Insights

Case Studies

Contact

  • Aramislaan 88,
  • 6213BV Maastricht, Netherlands
  • +31 6 55 88 71 96
  • contact@partners4access.com

P4A Services

For all access and Rare Disease related overview enquiries